BTAIQ insider buying and SEC filings, explained
BioXcel Therapeutics, Inc. · CIK 1720893
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$43K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 20, 2026 | Planned (10b5-1) | Frank Yocca (Chief Scientific Officer) sold 6,845 shares at about $1.09 ($7K), marked as a 10b5-1 plan trade. Holdings down 21% to 26,175 shares. | SEC filing Filed May 22, 2026 |
| May 20, 2026 | Planned (10b5-1) | Javier Rodriguez (Chief Legal Officer) sold 6,560 shares at about $1.08 ($7K), marked as a 10b5-1 plan trade. Holdings down 20% to 26,803 shares. | SEC filing Filed May 22, 2026 |
| May 20, 2026 | Planned (10b5-1) | Richard I Steinhart (CFO) sold 6,845 shares at about $1.09 ($7K), marked as a 10b5-1 plan trade. Holdings down 21% to 26,300 shares. | SEC filing Filed May 22, 2026 |
| May 20, 2026 | Planned (10b5-1) | Vimal Mehta (CEO and Director) sold 19,419 shares at about $1.09 ($21K), marked as a 10b5-1 plan trade. Holdings down 22% to 69,598 shares. | SEC filing Filed May 22, 2026 |
33 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BTAIQ in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.